Introduction
The search for novel anorectic agents to target the rapidly increasing worldwide prevalence of obesity has become of great importance in today's pharmaceutical research (Bloom et al., 2008; Hussain and Bloom, 2011) . Several fine-tuned peptidergic systems underlie the regulation of energy homeostasis, food intake, and body weight (Zac-Varghese et al., 2010; Pandit et al., 2011) . Two key players among those peptides are leptin and ghrelin, whose systems are closely intertwined (for reviews see: Dietrich and Horvath, 2009; Shan and Yeo, 2011) . Hypothalamic circuits, which are crucial for the regulation of food intake, are targets of both leptin and ghrelin. In a reciprocal manner, the two peptides act co-ordinated and independently, with a preprandial increase in ghrelin and decrease in leptin levels (Bagnasco et al., 2002) . Antagonism of the orexigenic effects of ghrelin, which leads to a reduction of food intake and body weight has become a new target in pharmacotherapeutic research for potent antiobesity agents (Els et al., 2010; Lim et al., 2010; Schellekens et al., 2010; Veldhuis and Bowers, 2010) . Furthermore, ghrelin not only initiates feeding but also plays a major role in the rewarding aspects of feeding (Egecioglu et al., 2010; Perello et al., 2010; Skibicka et al., 2011a Skibicka et al., , 2011b .
To investigate the role of peptidergic systems in the regulation of food intake and energy homeostasis, animal models of obesity are critical tools (for reviews see : Inui, 2000; Heinrichs, 2001; Balthasar, 2006; Vickers et al., 2011) . One widely used mouse model of obesity and the metabolic syndrome is the leptin-deficient ob/ob mouse (Campfield et al., 1995; Halaas et al., 1995; Pelleymounter et al., 1995) . In this mouse model, we have previously shown that leptin deficiency does not impair appetitive learning and motivation in a Y-maze and in a progressive-ratio operant task. Furthermore, ob/ob mice displayed sensitivity to the anorectic agent fenfluramine (Finger et al., 2010a (Finger et al., , 2010b . Moreover, we have recently shown in a cumulative food-intake task that the response to ghrelin receptor antagonism is dependent on the time of day and the satiety state in ob/ob mice (Finger et al., 2011) .
Although antagonism of the ghrelin receptor has anorectic effects in simple feeding tasks (Asakawa et al., 2003; Finger et al., 2011) , appetite research needs to create a broader behavioral profile describing the effects of an orexigenic or anorexigenic compound on not only food intake, but also satiety behavior. One assay to distinguish between the several behaviors involved in feeding and satiety and their natural progression is the behavioral satiety sequence (BSS). This paradigm was first established by Antin et al. (1975) and describes the natural sequence of behaviors displayed by a subject during and after feeding. After food intake, a gradual transition to grooming and resting behavior can be observed and this sequence is sensitive to drugs affecting the motivation to eat and satiety. To date, this paradigm has proven to be useful in the characterization of several anorectic agents, for example, fenfluramine (for review see: Halford et al., 1998; Rodgers et al., 2010) , as it gives insight into the fine structure of feeding and satiety behaviors. These observations are of substantial importance with regard to the efficacy of agents involved in the modulation of food intake and feeding behavior, as analysis of these satiety patterns reaches beyond quantitative food intake parameters (Rodgers et al., 2010) . This technique, furthermore, allows dissociation between natural anorexigenic/orexigenic drug responses and adverse side effects. This aspect is crucial with regard to the development of novel food-intake modulating agents and their safety and physiological impact. It is, therefore, very surprising that many of the neuropeptides critically involved in feeding and satiety, such as neuropeptide Y, galanin, glucagon-like peptide, leptin, agouti-related protein, ghrelin, melanocortin, obestatin, and pancreatic polypeptide, have not yet been studied extensively using this technique (Halford et al., 1998; Rodgers et al., 2010; Vickers et al., 2011) . Furthermore, there are to date, to our knowledge, no studies on the impact of leptin deficiency on the profile of the BSS.
We, therefore, sought to characterize the satiety profile of leptin-deficient ob/ob mice and their lean controls in response to ghrelin receptor ligands in BSS. This can give insight into the effect of leptin deficiency on behaviors involved in satiety processes and furthermore create a detailed behavioral profile of the effects of agonism and antagonism at the ghrelin receptor in feeding and satiety behaviors.
Methods

Subjects
In this study, male leptin-deficient ob/ob mice (n = 8) and their lean controls (n = 8; Harlan, UK) were used. On the date of arrival, mice were 5 weeks old. Subjects were housed in standard holding cages in groups of four, with a separation of genotypes. The holding room was temperature (21 ± 11C) and humidity (55 ± 10%) controlled and under a 12-h light/dark cycle (lights on 7.45 a.m.). Water was freely available throughout the whole study. Subjects were kept on a free-feeding schedule (standard lab chow: 2018S Teklad Global 18% protein rodent diet), unless stated otherwise for individual crossover designs.
All experiments were conducted in accordance with the European Directive 86/609/EEC, the Recommendation 2007/526/65/EC and approved by the Animal Experimentation Ethics Committee of University College Cork.
Behavioral satiety sequence BSS was carried out as described for mice (Vickers et al., 1996 (Vickers et al., , 1999 Pringle et al., 2008) . Mice were brought into the testing room 15 min before testing. Experiments were performed in the first 2 h after the onset of darkness under dimmed lights (4lux). Four subjects (2 ob/ob and 2 lean) were tested at the same time. Each mouse was placed into a clear plastic box (35 Â 25 Â 20 cm) containing a very thin layer of sawdust to reduce anxiogenic properties. A clear petri dish containing 10 g of wet mash (powdered chow, water, ratio 2 : 3) was placed into the centre of the testing box. Food was prepared fresh 1 h before the start of the experiment. Behavior was scored in four main categories: Feeding (eating, transporting, or sniffing food), exploration (walking in the box, rearing), grooming, and resting (immobile position, eyes open or closed). Each subject was observed individually and behavior was evaluated with one overall score every 30 s for the duration of 40 min. Therefore, each of the four mice received a total number of 80 scores. At the end of the test, mice were removed from the testing box, placed back into their homecage, and the testing boxes were cleaned.
Drugs and experimental design
Rat ghrelin (Innovagen AB, Lund, Sweden) and (DLys 3 )-GHRP-6 (Bachem, Weil am Rhein, Germany) were diluted fresh in 0.9% sterile saline. (D-Lys 3 )-GHRP-6 is a widely in vivo and in vitro studied and applied ghrelinreceptor antagonist (Beck et al., 2004; Kitazawa et al., 2005) , with strong antagonistic activity, the GHSR1a and low affinity at melanocortin receptors (Schiöth et al., 1997) . Peripheral administration of the antagonist (DLys 3 )-GHRP-6 has previously been shown to have similar effects compared with central administration (Asakawa et al., 2003) through its activity at ghrelin receptors in the arcuate nucleus, where the blood-brain barrier is incomplete (Pulman et al., 2006) . Mice received the drug or vehicle solution (0.9% sterile saline) intraperitoneally in a volume of 0.1 ml/10 g of bodyweight immediately before the start of the test procedures. All drugs were applied in a crossover design (Finger et al., 2011) . Half of the mice were tested per day (4 ob/ob and 4 lean) and one drug session was followed by 4 days of experimental break.
Drugs were applied and counterbalanced for genotype, testing time and day, and testing box and location within the room. Before drug testing, subjects were habituated to the testing apparatus, the wet mash diet, and to the procedure of intraperitoneal injections for 4 days. All mice then received four sessions of baseline testing. To test the orexigenic effects of ghrelin on the BSS, free-fed mice were injected intraperitoneally with ghrelin (0 or 2 nmol/10 g, respectively). Anorexigenic effects on BSS behavior by antagonism at the ghrelin receptor were assessed with the antagonist (D-Lys 3 )-GHRP-6 (0, 66.6, and 133.3 nmol/10 g) in 24-h food-deprived mice. Finally, both compounds were applied simultaneously [ghrelin, 2 nmol/10 g; (D-Lys 3 )-GHRP-6, 66.6 nmol/10 g] and BSS behavior was observed. For all drugs, testing started immediately after injection. Doses and route of administration of ghrelin and the ghrelin receptor antagonist were based on our previous experiments in a cumulative food intake paradigm (Finger et al., 2011) .
Statistical analysis
Statistical analysis for all tests was conducted using repeated-measures two-way analysis of variance (ANO-VA) for the assessment of overall effects. To further explore the effects of drug and genotype in the individual time bins, two-way ANOVA was carried out for significant overall effects followed by least significant difference post-hoc tests for comparison of drug groups within genotypes. Differences between genotypes for baseline assessment were analysed using repeated-measures ANOVA followed by estimation of parameters. Analysis of quantitive food intake was performed by two-way ANOVA, followed by least significant difference post-hoc tests. All tests were carried out at a significance level of a P value of less than 0.05. All analyses were carried out using with SPSS 15.0 for windows (SPSS Inc., Chicago, Illinois, USA). All graphs show mean values.
Results
Effects of leptin deficiency on the behavioral satiety sequence pattern Leptin-deficient ob/ob mice displayed a different baseline behavioral satiety pattern compared with lean control mice in a free-feeding state (Fig. 1) . Although feeding [genotype: F(1,14) = 24.42; P < 0.001] and resting behavior [genotype: F(1,14) = 31.68; P < 0.001; time Â genotype: F(7,98) = 5.58; P < 0.001] were more prominent in ob/ob mice, their exploratory activity was overall significantly decreased [genotype: F(1,14) = 35.36; P < 0.001; time Â genotype: F(7,98) = 2.66; P < 0.02].
Effects of ghrelin and (D-Lys
3 )-GHRP-6 on the behavioral satiety sequence Orexigenic effects of ghrelin (2 nmol/10 g) Ghrelin increased feeding behavior independent of genotype [drug, F(1,28) = 12.36; P < 0.002] and differences between ob/ob and lean mice remained [ Fig. 2 ; genotype, F(1,28) < 13.66; P < 0.001; time Â genotype: F(7,196) = 5.63; P < 0.001]. Orexigenic effects of ghrelin were time dependent [time Â drug: F(7,196) = 2.98; P < 0.005] and limited to the first 10 testing minutes [time bin 1: F(1,28) = 6.24, P < 0.02; time bin 2: F(1,28) = 39.34; P < 0.001]. However, this effect was more pronounced in lean mice, showing a shift in the satiety sequence, whereas ob/ob mice only presented with an increase feeding activity in time bin 2, and the shift from eating to resting was equally timed independent of the drug. This was further supported by the amount of food ingested [drug overall: F(1,28) = 7.82; P = 0.01], whereas lean mice significantly increased the food intake in response to ghrelin administration (vehicle: 0.778 g ± 0.074; ghrelin 1.053 g ± 0.048; P < 0.05), there was no change in ob/ob mice [vehicle: 1.127 g ± 0.119; ghrelin: 1.327 g ± 0.084; not significant (NS)].
Effects of (D-Lys 3 )-GHRP-6 (66.6 nmol/10 g) in 24-h food-deprived mice Feeding behavior showed the genotypic differences between groups but was unaffected by the administration of (D-Lys 3 )-GHRP-6 [66.6 nmol/10 g; Fig. 3 ; genotype, F(1,28) = 11.31; P < 0.002]. However, the effects of (D-Lys 3 )-GHRP-6 were more pronounced in the other parameters; exploratory activity was reduced in lean subjects after drug administration in time bins 2 and 3 Leptin deficiency changes the behavioral satiety sequence profile. Leptin-deficient obese mice display, in a free-feeding fed state, increased feeding and resting, but decreased exploratory behavior in the behavioral satiety sequence. N = 8/genotype; repeated measures followed by estimation of parameters; *P < 0.05; **P < 0.01; ***P < 0.001 compared with lean control mice.
(P < 0.01, < 0.02), whereas obese mice showed a less pronounced reduction in the exploratory activity (time bin 2; P < 0.05). This reduction in exploration in lean subjects was replaced by an increase in grooming behavior (time bin 1 and 2 both; P < 0.001) followed by an increase in resting behavior (time bin 3; P < 0.02) accompanied by mild abdominal cramping. These abdominal cramps were reflected by an abnormal stretching behavior detected by close observation of the individual subjects. Both increased resting and abdominal cramping can be interpreted as side effects of the drug. However, it would be beneficial to separately assess these effects to determine the strength of the side effects.
Quantitative changes in the food intake, however, were, as for ghrelin, only observed in lean subjects after administration of (D-Lys 3 )-GHRP-6 (66.6 nmol/10 g; drug overall: F(1,28) = 7.77; P < 0.01), with a reduction in the food intake from 1.622g ± 0.087 in vehicle to 1.174g ± 0.1093 in drug-treated mice (P < 0.02). In obese subjects, this reduction was not significant, with 1.899g ± 0.161 in vehicle and 1.671 g ± 0.116 in drugtreated mice (NS).
Effects of (D-Lys
3 )-GHRP-6 (133.3 nmol/10 g) in 24-h food-deprived mice
Anorexigenic effects of the ghrelin receptor antagonist decreased the feeding percentage in both genotypes time dependently [ Fig. 4 ; time Â genotype Â drug, F(7,196) = 2.79; P < 0.01; drug, F(1,28) = 25.17; P < 0.001; genotype, F(1,28) = 79.64; P < 0.001; time Â genotype, F(7,196) = 3.65; P < 0.001; time Â drug, F(7,196) = 2.72; P < 0.01], with a stronger and longer-lasting decrease in feeding behavior in lean mice compared with ob/ob subjects. Again, the adverse effects of the antagonist were more prominent in lean subjects and resulted in increased grooming in the first time bin (P < 0.001) followed by increased resting and abdominal cramping in the following five time intervals (P < 0.001 in each), leading to a substantial decrease in the exploratory activity in this time window (bin 1, P < 0.01; bin 2-5, P < 0.001; bin 6, P < 0.02). Orexigenic actions of ghrelin in the behavioral satiety sequence. Peripheral administration of ghrelin (2 nmol/10 g) has appetite-stimulating effects in lean and leptin-deficient obese mice. N = 8/genotype; two-way repeated-measures analysis of variance; least significant difference post-hoc test for individual time bins; *P < 0.05; **P < 0.01; ***P < 0.001; drug compared with vehicle within genotype.
Quantitatively, food intake was now strongly reduced in both genotypes (drug: F(1,28) = 33.03; P < 0.001), with a decrease in lean mice from 1.662 g ± 0.095 to 0.772 g ± 0.057 (P < 0.001) and in obese subjects from 2.197 g ± 0.175 to 1.653 g ± 0.139 (P = 0.005).
Effects of ghrelin (2 nmol/10 g) and (D-Lys 3 )-GHRP-6
(66.6 nmol/10 g)
The ghrelin receptor antagonist (66.6 nmol/10 g) successfully counteracted the effects of ghrelin (2 nmol/10 g) on feeding behavior as demonstrated by the combination of both compounds having no effect on BSS ( Fig. 5 ; overall effect of drug NS), whereas overall temporal and genotypic patterns remained [time: F(7,196) = 3.81; P < 0.001; genotype F(1,28) = 21.99; P < 0.001; time Â genotype F(7,196) = 2.74; P < 0.01].
However, previously observed side effects seen in an increase in grooming and resting and decreased exploratory activity remained, again predominantly in the lean group. Here, exploration was decreased in time bins 1-5 (all P < 0.001), substituted by an increased grooming in time bins 1 and 2 (P < 0.001, < 0.005) followed by an increased resting in time bins 2-5 (P < 0.05, < 0.005, < 0.001, < 0.01, respectively).
The amount eaten was not affected by coadministration of ghrelin and the antagonist in either genotype [drug: F(1,28) = 1.82; NS], with similar amounts eaten within the lean (vehicle: 0.568 g ± 0.072; drug: 0.723 g ± 0.065) and obese (vehicle: 1.014 g ± 0.142; drug: 1.245 g ± 0.179) groups.
Discussion
This study is, to our knowledge, the first attempt to characterize ghrelin receptor ligands in BSS. Furthermore, and somewhat surprisingly, it is also to our knowledge the first study using leptin-deficient mice, a widely used model of obesity and the metabolic syndrome, in this paradigm.
In the first part of the study, we have shown the effect of leptin deficiency on the BSS profile. In a free-feeding state, leptin-deficient mice displayed increased feeding )-GHRP-6 fails to elicit anorectic effects at a dose of 66.6 nmol/10 g in 24-h food-deprived mice; N = 8/genotype; two-way repeated-measures analysis of variance; least significant difference post-hoc test for individual time bins; *P < 0.05; **P < 0.01; ***P < 0.001; drug compared with vehicle within genotype.
and resting behavior in BSS compared with lean control mice, but showed decreased exploratory activity. The expected BSS pattern with a transition from eating via grooming to a resting state was more pronounced in obese mice, as lean control mice showed lower eating activity and an overall slower transition into the resting state. These observations demonstrate the utility of the BSS paradigm, as it gives a good phenotype characterization of the ob/ob mice with their typical, previously reported hypolocomotion, hyperphagia, and oscitancy (Halaas et al., 1995; Pelleymounter et al., 1995; Fulton et al., 2006; Laposky et al., 2006) . However, they also demonstrate the limitations of the BSS paradigm [previously discussed for mice by Pringle et al., (2008) ] as lean untreated mice that often display a high amount of exploratory activity and thereby fail to complete the full satiety sequence.
We then assessed the effects of peripheral administration of ghrelin on the BSS pattern in freely fed mice. The orexigenic properties of ghrelin have been widely studied in animals and humans, and central and peripheral administration of the peptide is known to stimulate the reward system, and to increase food intake and body weight gain (Tschöp et al., 2000; Arvat et al., 2001; Nakazato et al., 2001; Wren et al., 2001; Drazen et al., 2006; Theander-Carrillo et al., 2006; Hotta et al., 2009; Dickson et al., 2011) . It was, therefore, of interest to investigate the effects of ghrelin in BSS. In this study, peripheral administration of ghrelin (2 nmol/10 g) increased the feeding behavior in both genotypes. However, the appetite-stimulating signal caused a more prominent change in lean than in ob/ob mice within the first three time bins of BSS. The stronger effect in lean subjects was further supported by their significant increase in the food intake after ghrelin administration, which was not observed in ob/ob mice.
Moreover, subjects presented with (acute) decreased exploration after ghrelin administration (Fig. 2) , which results from an increased feeding activity after the administration of the orexigenic peptide. However, recent studies have described an increase in locomotor Time bins Time bins * * * * * * * * * * * * * * * * * * * * * * * * * * *
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Ob/ob mice are less sensitive to the anorectic effects of the ghrelin receptor antagonist (D-Lys 3 )-GHRP-6. At a dose of 133.3 nmol/10 g, the ghrelin receptor antagonist (D-Lys activity after ghrelin administration due to the activation of the midbrain dopaminergic system (Jerlhag et al., 2006 (Jerlhag et al., , 2007 . These observations may indicate a separation of ghrelin-induced locomotor effects in reward-associated and natural feeding and satiety behaviors.
Of note, lean control mice failed to elicit a complete BSS pattern after vehicle administration, as baseline feeding was low and a transition to the resting state was only seen by trend toward the end of the testing period. The observation of low baseline, but high exploratory activity is not uncommon in mice, as recently demonstrated (Pringle et al., 2008; Morris et al., 2009) ; however, this complicates the interpretation and utility of the BSS paradigm in lean, untreated mice with high-baseline locomotor activity. To highlight transitions between stages in lean mice, it would be beneficial in future studies to use a time-based representation (Halford et al., 1998) as seen in many rat studies (Ishii et al., 2003) and not the score-based technique, which is more frequently used in mice (Vickers et al., 1999; Pringle et al., 2008; Morris et al., 2009) . But overall, the orexigenic peptide ghrelin triggered a natural appetite-stimulated profile response in the BSS predominantly in lean mice without disrupting its pattern.
Antagonism at the ghrelin receptor with peripherally administered (D-Lys 3 )-GHRP-6, after 24 h of food restriction, failed to show anorectic properties at a low dose (66.6 nmol/10 g) in BSS in mice of both genotypes. It, however, reduced the overall amount of food eaten only in lean mice. This enhanced sensitivity to the antagonist in lean mice was further confirmed in observation of the additional BSS parameters. Here, (D-Lys 3 )-GHRP-6 stimulated grooming behavior that caused mild abdominal cramps, seen in abdominal stretching. It, furthermore, increased resting and decreased exploratory activity in lean control mice in the first 10 min of the test. Administration of a higher dose of the ghrelin receptor antagonist (133.3 nmol/10 g) significantly reduced feeding behavior and quantitative food intake in both genotypes. But again, the antagonist caused a strong disruption of the BSS only in lean control mice. Control mice displayed predominantly resting behavior during the first 30 test minutes with a strong suppression of feeding and occasional abdominal cramps. In contrast, ob/ob mice displayed a slightly accelerated onset of the BSS, demonstrating the anorectic effects of the ghrelin receptor antagonist.
Antagonist activity was studied after food restriction in all mice, whereas ghrelinergic effects were observed in freely fed animals. After food restriction, baseline feeding values in lean control mice were increased and they displayed a more typical satiety sequence. This demonstrated the sensitivity of the BSS method to changes in feeding protocols.
After administration of both compounds, ghrelin (2 nmol/ 10 g) and (D-Lys 3 )-GHRP-6 (66.6 nmol/10 g), in freely fed mice, no change in the percentage of feeding activity was displayed in either of the genotypes. Nonetheless, a disruption of the BSS pattern remained in lean control mice within the first half of the test, with an increase in grooming and resting behavior and a decrease in exploration. Leptin-deficient ob/ob mice, on the other hand, showed decreased grooming activity, but showed also a tendency for decreased exploration and increased resting behavior.
Overall, we show in this study that leptin-deficient mice present with a changed baseline profile in the BSS, but decreased sensitivity to the orexigenic agent ghrelin and to the anorectic ghrelin receptor antagonist. This was evidenced by a less pronounced increase after agonism and decrease after antagonism in feeding activity, and a diminished disruption of the BSS pattern, which was very prominent in lean control mice. The decreased sensitivity to ghrelin receptor ligands in obese subjects has recently been discussed as ghrelin resistance in diet-induced obese subjects (Briggs and Andrews, 2011) . Furthermore, these findings are to some extent comparable with the results from cumulative food intake experiments (Asakawa et al., 2003; Finger et al., 2011) . In these studies, food-restricted ob/ob mice do show an anorectic response to a high dose of (D-Lys 3 )-GHRP-6, but, as in this study, it is blunted in comparison with the magnitude of the decrease in feeding seen in the lean control mice under the same conditions. Furthermore, in the dark cycle, ob/ob mice showed a decreased orexigenic response to ghrelin compared with lean controls (Finger et al., 2011) , further bolstering the hypothesis of decreased ghrelin sensitivity in obese subjects.
With the results gained in this BSS paradigm, we can now conclude that ob/ob mice respond less than lean controls to an administration of ghrelin in a free-feeding state, and are less sensitive to the adverse effects (overt cramping) arising from administration of the ghrelin receptor antagonist (D-Lys 3 )-GHRP-6 in lean mice. Furthermore, obese mice in a state of food deprivation also present with decreased response to the anorectic properties of ghrelin antagonism.
The advantage of the BSS procedure over other simple food intake tasks includes its ability to detect adverse side effects. However, in this study, a clear differential score between cramping and resting behavior has not been performed, but should be assessed in future studies to represent the magnitude of the observed side effects. Interestingly, such overt cramping as observed in lean control mice after administration of 66.6 nmol/10 g and 133.3 nmol/10 g doses of (D-Lys 3 )-GHRP-6, was similarly described in a study on the anorectic properties of cholecystokinin in the BSS in rats (Verbaeys et al., 2009) . Here, a dose of 16 mg/kg of pegylated-cholecystokinintriggered abdominal cramping but produced anorectic effects at lower doses.
In conclusion, our data show that BSS is ideal for parsing the role of the ghrelinergic system in satiety. Overall, we demonstrate that the hypophagia, in response to the ghrelin receptor antagonist D-Lys 3 -GHRP-6, may not solely be due to natural satiety mechanisms, but also due to inhibition of feeding as a result of adverse neurobiological effects. Moreover, these studies offer further evidence for the utility of the BSS as a sensitive screening tool to reveal properties of orexigenic and anorexigenic compounds. It targets not only food intake as a quantitative readout, but also provides a broader profiling of several behaviors involved in feeding and their natural succession. As we show in this study, this method not only serves to describe phenotypes of genetically modified mice (Pringle et al., 2008) , but also detects changes in sensitivity to orexigenic or anorexigenic agents in these mutant mice. It would be, therefore, of great importance for future studies to assess the use of novel anorectic peptides in different animal models of obesity.
